Literature DB >> 21206395

Clostridium difficile infection among children with cancer.

Eric Tai1, Lisa C Richardson, Julie Townsend, Elizabeth Howard, L Clifford Mcdonald.   

Abstract

We used data from the Kids' Inpatient Database to examine Clostridium difficile infection (CDI) among children with cancer. The CDI rate was 15 times greater among children with cancer compared with those without cancer. Children with cancer accounted for 21% of all pediatric CDI cases. Increased adherence to infection control recommendations is needed to address CDI in children with cancer.

Entities:  

Mesh：

Year:  2011        PMID： 21206395     DOI： 10.1097/INF.0b013e31820970d1

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  16 in total

1.  Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia.

Authors:  Yilun Sun; Rachael L Huskey; Li Tang; Hiroto Inaba; Aditya H Gaur; Raul Ribeiro; Jeffrey E Rubnitz; Joshua Wolf
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

2.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

3.  Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia.

Authors:  Brian T Fisher; Julia Shaklee Sammons; Yimei Li; Peter de Blank; Alix E Seif; Yuan-Shung Huang; Marko Kavcic; Sarah Klieger; Tracey Harris; Kari Torp; Douglas Rheam; Ami Shah; Richard Aplenc
Journal:  J Pediatric Infect Dis Soc       Date:  2014-02-16       Impact factor: 3.164

4.  Vancomycin Use for Pediatric Clostridium difficile Infection Is Increasing and Associated with Specific Patient Characteristics.

Authors:  Hayden T Schwenk; Dionne A Graham; Tanvi S Sharma; Thomas J Sandora
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

5.  Clostridium difficile as a cause of healthcare-associated diarrhoea among children in Auckland, New Zealand: clinical and molecular epidemiology.

Authors:  V Sathyendran; G N McAuliffe; T Swager; J T Freeman; S L Taylor; S A Roberts
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-09       Impact factor: 3.267

Review 6.  Clostridium difficile Infection in Children: Current State and Unanswered Questions.

Authors:  Pranita D Tamma; Thomas J Sandora
Journal:  J Pediatric Infect Dis Soc       Date:  2012-07-25       Impact factor: 3.164

Review 7.  Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections.

Authors:  Lynne Vernice McFarland; Metehan Ozen; Ener Cagri Dinleyici; Shan Goh
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

8.  Intensity of Therapy for Malignancy and Risk for Recurrent and Complicated Clostridium difficile Infection in Children.

Authors:  Zachary I Willis; Maribeth R Nicholson; Adam J Esbenshade; Meng Xu; James C Slaughter; Debra L Friedman; Kathryn M Edwards; Maria C Di Pentima
Journal:  J Pediatr Hematol Oncol       Date:  2019-08       Impact factor: 1.289

9.  Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia.

Authors:  Joshua Wolf; Li Tang; Patricia M Flynn; Ching-Hon Pui; Aditya H Gaur; Yilun Sun; Hiroto Inaba; Tracy Stewart; Randall T Hayden; Hana Hakim; Sima Jeha
Journal:  Clin Infect Dis       Date:  2017-11-13       Impact factor: 9.079

10.  Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer.

Authors:  Peter de Blank; Theoklis Zaoutis; Brian Fisher; Andrea Troxel; Jason Kim; Richard Aplenc
Journal:  J Pediatr       Date:  2013-03-08       Impact factor: 4.406
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.